Following on from the UK government decision to trigger Article 50 of the Treaty on European Union, and thereby provide notice of the country’s intention to leave the European Union (EU), one near-term impact will be the requirement for the European Medicines Agency (EMA) to move from the UK to a new location. The EMA, located in London since 1995, is a decentralised agency of the EU which evaluates and authorises medical products and is responsible for protecting and promoting human (and animal) health in the 28 Member States of the EU, in addition to the jurisdictions of the European Economic Area (EEA).